key: cord-0901137-a9kfzygv authors: Ikegame, Satoshi; Siddiquey, Mohammed N. A.; Hung, Chuan-Tien; Haas, Griffin; Brambilla, Luca; Oguntuyo, Kasopefoluwa Y.; Kowdle, Shreyas; Vilardo, Ariel Esteban; Edelstein, Alexis; Perandones, Claudia; Kamil, Jeremy P.; Lee, Benhur title: Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants date: 2021-04-08 journal: Res Sq DOI: 10.21203/rs.3.rs-400230/v1 sha: 396934d08aa8a592d8c7f6d31b98c97b75d0784f doc_id: 901137 cord_uid: a9kfzygv The novel pandemic betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected at least 120 million people since its identification as the cause of a December 2019 viral pneumonia outbreak in Wuhan, China(1,2). Despite the unprecedented pace of vaccine development, with six vaccines already in use worldwide, the emergence of SARS-CoV-2 ‘variants of concern’ (VOC) across diverse geographic locales have prompted re-evaluation of strategies to achieve universal vaccination(3). All three officially designated VOC carry Spike (S) polymorphisms thought to enable escape from neutralizing antibodies elicited during initial waves of the pandemic(4–8). Here, we characterize the biological consequences of the ensemble of S mutations present in VOC lineages B.1.1.7 (501Y.V1) and B.1.351 (501Y.V2). Using a replication-competent EGFP-reporter vesicular stomatitis virus (VSV) system, rcVSV-CoV2-S, which encodes S from SARS coronavirus 2 in place of VSV-G, and coupled with a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient S-mediated infection, we determined that only 1 out of 12 serum samples from a cohort of recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed effective neutralization (IC(90)) of rcVSV-CoV2-S: B.1.351 at full serum strength. The same set of sera efficiently neutralized S from B.1.1.7 and showed only moderately reduced activity against S carrying the E484K substitution alone. Taken together, our data suggest that control of some emergent SARS-CoV-2 variants may benefit from updated vaccines. ABSTRACT. 24 The novel pandemic betacoronavirus, severe acute respiratory syndrome coronavirus 2 25 (SARS-CoV-2), has infected at least 120 million people since its identification as the 26 cause of a December 2019 viral pneumonia outbreak in Wuhan, China 1,2 . Despite the 27 unprecedented pace of vaccine development, with six vaccines already in use 28 worldwide, the emergence of SARS-CoV-2 'variants of concern' (VOC) across diverse 29 geographic locales have prompted re-evaluation of strategies to achieve universal 30 vaccination 3 . All three officially designated VOC carry Spike (S) polymorphisms thought 31 to enable escape from neutralizing antibodies elicited during initial waves of the 41 against S carrying the E484K substitution alone. Taken together, our data suggest that 42 control of some emergent SARS-CoV-2 variants may benefit from updated vaccines. 43 44 pre-fusion conformer. Vaccines that do not utilize pre-fusion "locked" S are expected to 86 produce lower levels of neutralizing antibodies, and hence may be less efficacious 87 against infection, even if they do protect against severe COVID-19. Indeed, a two-dose 88 regimen of the AstraZeneca ChAdOx1 based vaccine, which does not use a "locked" S, 89 did not protect against mild-to-moderate COVID-19 in S. Africa, where 93% of COVID- Robust reverse genetics for generating replication-competent VSV expressing 122 SARS-CoV-2 Spike proteins. 123 Several groups have now generated replication-competent VSV expressing SARS-CoV-124 2 spike in place of VSV-G (rcVSV-CoV2-S) [34] [35] [36] 37 . These rcVSV-CoV2-S can be used in 125 BSL-2 compatible virus neutralization assays (VNAs), which correlate very well with 126 VNAs using live SARS-CoV-2 (Spearman's r > 0.9 across multiple studies). rcVSV- CoV2-S has been assessed as a candidate vaccine 36, 38 , and used in forward genetics 128 experiments to generate antibody escape mutants or perform comprehensive epitope 129 mapping studies 39, 26, 37 . Indeed, the now concerning E484K mutation, present in many 130 variants of concern (VOC), was identified as an antibody escape mutation using rcVSV- A key public health concern related to emergent SARS-CoV-2 variants is that by 205 incrementally accruing mutations that escape neutralizing antibodies, they will penetrate 206 herd immunity and spread to reach unvaccinated individuals, some of whom will be 207 susceptible to severe or fatal disease. Fig. S3 ). One serum had little to no detectable neutralizing activity against B. While the E484K substitution appears to be a common route of escape from many 253 RBD-targeting monoclonal antibodies, it is somewhat surprising that a single mutation 254 can confer a significant degree of neutralization resistance from polyclonal responses. Nonetheless, our data show that resistance conferred by E484K mutation be overcome Table 2 ). We gratefully acknowledge all submitting authors and collecting authors on whose work 395 this research is based, and to all researchers, clinicians, and public health authorities 396 who make SARS-CoV-2 sequence data available in a timely manner via the GISAID 397 initiative 57, 58 . Acknowledgement of B.1.1.7 and B.1.351 viruses used for selection of S variants evaluated in this study. Bars represent the average of 3 replicates with error bars indicating standard deviation. A two-way ANOVA was used to compare the differences between cell lines at any given dilution. Adjusted p values from Tukey's multiple comparisons test are given (ns; not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). Neutralization is represented by the reciprocal 50% inhibitory dilution factor (1/IC50). Sera samples with no appreciable neutralization against a given virus were assigned a defined 1/IC50 value of 1.0, as values ≤1 are not physiological (Grey shaded area). Dashed line indicates the lowest serum dilution tested (1/IC50 = 20). Geometric mean titers (GMT and 95% CI) for the neutralizing activity of all vaccine sera are indicated below each of the viral spike proteins examined . NS; not significant, *; p<0.05, p < 0.01; ** are adjusted p values from nonparametric one-way ANOVA with Dunn's multiple comparisons test. (C) For each serum sample, the fold-change in IC50 (reciprocal inhibitory dilution factor) against the indicated variant and mutant spike proteins relative to its IC50 against wild-type (WT) spike (set at 1) is plotted. Adjusted p values were calculated as in (B). Medians are represented by the bars and whiskers demarcate the 95% CI. Neutralization dose-response curves were performed in triplicates, and the mean values from each triplicate experiment are shown as the single data points for each sera sample. Dashed lines indicate quadrants of high/low IC50 and high/low slope. Fig. S2 . Sputnik vaccine elicits qualitatively different polyclonal responses against SARS-CoV-2 Spike. The full neutralization dose-response curves for all four classes of sera described in Fig. 3 are shown. Data points are mean of 3 independent replicates with error bars representing S.D. Infection (GFP+ cells) at each serum dilution was normalized to that obtained in the absence of any serum (set at 100%). Nonlinear regression of log [reciprocal serum dilution] versus normalized infection was performed using GraphPad PRISM (v9.0.1). Dotted lines represent 50% of maximal infection. Clinical features of patients infected with 2019 novel coronavirus in Wuhan COVID-19 Map -Johns Hopkins Coronavirus Resource Center Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera Increased Resistance of SARS-CoV-2 Variant P. 1 to Antibody Neutralization Neutralizing Activity of BNT162b2-Elicited Serum Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18--59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Interim Results of a Phase 1-2a Trial of Ad26 Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate What level of neutralising antibody protects from COVID-19? bioRxiv Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2. Cold Spring Harbor Laboratory Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape. Cold Spring Harbor Laboratory A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Safety and immunogenicity of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies Ad26 vector-based COVID-19 vaccine encoding a prefusionstabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses Safety and Immunogenicity of Two RNA-Based Covid-19 SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen Escape of SARS-CoV-2 501Y. V2 from neutralization by convalescent plasma. medRxiv SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines New SARS-CoV-2 Variants -Clinical, Public Health, and Vaccine Implications … respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional … A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 A serological assay to detect SARS-CoV-2 seroconversion in humans Efficient and Robust Paramyxoviridae Reverse Genetics Systems Data, disease and diplomacy: GISAID's innovative contribution to global health Global initiative on sharing all influenza data -from vision to reality The maximal T7 promoter (T7prom) followed by a hammer-head ribozyme (HhRbz) and the HDV ribozyme (HDVRbz) plus T7 terminator (T7term) are positioned at the 3' and 5' ends of the viral cDNA, respectively. An EGFP(E) transcriptional unit is placed at the 3' terminus to allow for high level transcription. SARS-CoV-2-S is cloned in place of VSV-G using the indicated restriction sites designed to facilitate easy exchange of spike variant or mutants. (B) For virus rescue, highly permissive 293T cells stably expressing human ACE2 and TMPRSS2 (293T-[ACE2+TMPRSS2], F8-2 clone) cells were transfected with the genome coding plasmid, helper plasmids encoding CMV-driven N, P, M, and L genes, and pCAGS encoding codon-optimized T7-RNA polymerase(T7opt). 48-72 hpi, transfected cells turn EGFP+ and start forming syncytia Extended Data Fig. S3. B.1.351 shows marked resistance to Sputnik vaccine sera neutralization Maximal Percent Inhibition (MPI) at full serum strength extrapolated from nonlinear regression of log(inhibitor) versus normalized response, variable slope curve. Model used is from PRISM v9.0 where Y= 100/(1+10^((LogIC50-X)*HillSlope))). Log IC50 and Hill slope values were obtained for each curve generated in Extended Data Fig. S2. For reciprocal serum dilution of 1 (10^0), X= 0